The global sales of Lateral Flow Assay in 2021 was held at US$ 7.2 Bn. With 4.7%, the projected market growth during 2022 – 2032 is expected to be significantly higher than the historical growth. Benchtop Readers is expected to be the highest revenue generating product, while Clinical Testing is considered to be the highest revenue generating application with a CAGR of 4.6% and 5% respectively during 2022 – 2032.
Given the multiple advantages that lateral flow technology provides, it is becoming the approach of choice for infectious disease diagnostics. The market’s growth can be due to the rising prevalence of infectious diseases, growing elderly population and the growing popularity of point-of-care testing.
The market is also expected to gain from the growing popularity of self-diagnosis, which is driving demand for home-based lateral flow assay devices. Continuing technological breakthroughs in the field of lateral flow tests are also boosting market expansion. These efforts are aimed at improving the selectivity, sensitivity, and quantitation of these tests. In addition, growth is boosted by the integration of enhanced quantification systems, novel labels, and simultaneous detection approaches.
For critical insights on this market, request for More Info – https://www.factmr.com/connectus/sample?flag=S&rep_id=7246
Market Segments Covered in Lateral Flow Assay Industry Analysis
-
By Product Type
- Lateral Flow Readers
- Digital/Mobile Readers
- Benchtop Readers
- Kits & Reagents
-
By Application
- Drug Development & Quality Testing
- Clinical Testing
- Veterinary Diagnostics
- Food safety & Environment Testing
-
By Technique
- Sandwich Assays
- Competitive Assays
- Multiplex Detection Assays
-
By Region
- North America
- Latin America
- Europe
- APAC
- MEA
Request more information about Report Methodology – https://www.factmr.com/connectus/sample?flag=RM&rep_id=7246
Competitive Analysis
Product approvals, new product releases, acquisitions, collaborations, and innovations are all important methods used by leading market players to maintain their market position.
According to the market research analysis, partnerships and expansion have been the prominent development in Lateral Flow Assay market in recent year. Abbott Laboratories; Thermo Fisher Scientific, Inc.; F. Hoffmann-La Roche AG; Bio-rad Laboratories, Inc.; Biomérieux SA; Quidel Corporation; Hologic, Inc.; Perkinelmer, Inc.; Merck KGAA; Becton, Dickinson and Company; Siemens Healthineers; Danaher Corporation; Qiagen N.V. are the prominent providers of Lateral Flow Assay services.
The leading players in the Lateral Flow Assay market have been implementing various tactics to increase growth potential over the next years. Furthermore, the presence of many rising and well-established firms has defined the market for Lateral Flow Assay. Well-known market players are pursuing a variety of tactics, including acquisitions, mergers, and new product releases. Some of the recent developments of key Lateral Flow Assay providers are as follows:
- In October 2021, Bio-Plex Pro human immunoglobulin A (IgA) and immunoglobulin M (IgM) SARS-CoV-2 antigen panels were launched by Bio-Rad Laboratories, a life science research and clinical diagnostic products firm, to detect IgA and IgM antibodies against four SARS-CoV-2 antigens.
- In September 2021, The FDA granted ANP Technologies Inc. authorization to use its NIDS COVID-19 Antigen Rapid Test Kit as a treatment for the act of NANs in children as well as adults with suspected COVID-19. Following analyses in the United States, this test utilizes a technology by ANP.
- In October 2020, Siemens Healthineers launched a rapid antigen test for the detection of SARS-CoV-2.
- In September 2020, Roche announced the launch of the SARS-CoV-2 fast antigen test for markets that accept the CE Mark. Roche also plans to apply to the US Food and Drug Administration for an Emergency Use Authorization (EUA) (FDA).
Similarly, recent developments related to companies offering Lateral Flow Assay have been tracked by the team at Fact.MR, which are available in the full report.
For in-depth competitive analysis, Buy Now – https://www.factmr.com/checkout/7246
What Factors are driving the Lateral Flow Assay Revenue in the US?
The presence of the key market leaders in the United States has facilitated lateral flow assays market growth in the country. Furthermore, a favorable reimbursement scenario and advanced point-of-care testing facilities promote the lateral flow assays market in the United States.
Alongside, the region’s high rate of respiratory illnesses such COVID-19, influenza, and RSV is driving up demand for detection and treatment. The availability of government funding for research and the presence of well-established healthcare infrastructure are expected to boost the market for lateral flow assays in the country. The National Institute of Health (NIH) spent US$ 248.7 Mn for the development of new technologies to overcome issues related with COVID-19 testing in July 2020.
For More Insight- https://www.factmr.com/article/124/latest-trends-in-the-healthcare-industry-how-has-it-transformed-businesses
About Us:
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analysed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com
